Actinium Pharmaceuticals (ATNM) said Wednesday it has completed enrolling subjects in a phase 3 trial evaluating Iomab-B as a potential treatment of...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Actinium Pharmaceuticals (ATNM) said Thursday it has been awarded patents in Europe and Japan for the composition and methods of administering its Iomab-B...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 275 Madison Avenue New York, New York 10016 |
| Phone | +1.646.677.3870 |
| Number of Employees | 30 |
| Recent SEC Filing | 11/12/2021 10-Q |
| Chairman & Chief Executive Officer | Sandesh Seth |
| Chief Financial Officer | Steve O'Loughlin |
| Chief Medical Officer | Avinash Desai |
| Vice President-Clinical Development | Mary Mei Chen |
| Price Open | $7.29 |
| Previous Close | $7.40 |
| 52 Week Range | $5.70 - 11.90 |
| Market Capitalization | $160.6 M |
| Shares Outstanding | 22.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/30/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.27 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -2,506.87% |
| Return on Equity | -34.52% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
